Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Everest Organics FCF Yield % Related Terms
Everest Organics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Everest Organics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Everest Organics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Everest Organics FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Everest Organics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Everest Organics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Everest Organics (BOM:524790) has a FCF Yield % of 0.32 as of Aug. 06, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Everest Organics and its competitors. According to the industry distribution chart, Everest Organics ranks #528 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 52.5%.
Is Everest Organics' FCF Yield % too high?
Everest Organics' current FCF Yield % is 0.32. The Drug Manufacturers industry median FCF Yield % is 0.71. Everest Organics' value of 0.32 is 54.9% below this industry median. Based on the distribution chart, Everest Organics ranks #528 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Everest Organics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Everest Organics' FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Everest Organics ranks #528 out of 1006 companies for FCF Yield %. This places Everest Organics in the lower half of its industry. The industry median FCF Yield % is 0.71. Everest Organics' value of 0.32 is 54.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.71, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Everest Organics's current FCF Yield % of 0.32 is 54.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Everest Organics and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Everest Organics's current FCF Yield % is 0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Organics stock overvalued right now?
Based on GuruFocus' analysis, Everest Organics (BOM:524790) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹129.34, compared to a current price of ₹307.15 — trading 137.5% above its estimated fair value. The current FCF Yield % is 0.32 and 54.9% below the Drug Manufacturers industry median of 0.71. Everest Organics' overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Everest Organics (BOM:524790), the current FCF Yield % is 0.32 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Everest Organics (BOM:524790) Overvalued in 2026?
Based on GuruFocus' analysis, Everest Organics stock appears to be overvalued.
The current stock price of ₹307.15 is trading 137.5% above its estimated GF Value™ of ₹129.34.
GuruFocus considers Everest Organics to be Significantly Overvalued.
Key valuation signals for BOM:524790:
FCF Yield %: 0.32
GF Value™: ₹129.34 vs. price of ₹307.15 (137.5% above fair value)
Industry Position: 54.9% below the Drug Manufacturers median (#528 of 1006)
No single metric tells the full story. See the BOM:524790 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Everest Organics Ltd is a pharmaceutical company. It is focused on manufacturing active pharmaceutical ingredients and intermediaries. The products offered by the company include Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole, and others. The company operates in one primary business segment namely Active Pharmaceutical Ingredients (API) and their intermediaries. Geographically, it derives a majority of its revenue from India.
47GF Score
Get the complete analysis for BOM:524790
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524790 has been successfully added to your 
